Pharmacologic Agents and Drugs for Mental Disorders (SBIR [R43/R44])

Applicants Eligible for this Grant

Small businesses

Additional Information on Eligibility

Only United States small business concerns (SBCs) are eligible to submit SBIR applications. A small business concern is one that, at the time of award for both Phase I and Phase II awards, meets all of the following criteria: - Is independently owned and operated, is not dominant in the field of operation in which it is proposing, has a place of business in the United States and operates primarily within the United States or makes a significant contribution to the US economy, and is organized for profit. - Is at least 51% owned and controlled by one or more individuals who are citizens of, or permanent resident aliens in, the United States. - Has, including its affiliates, an average number of employees for the preceding 12 months not exceeding 500, and meets the other regulatory requirements found in 13 C.F.R. Part 121. Business concerns are generally considered to be affiliates of one another when either directly or indirectly, (a) one concern controls or has the power to control the other; or (b) a third-party/parties controls or has the power to control both. Control can be exercised through common ownership, common management, and contractual relationships. The term "affiliates" is defined in greater detail in 13 C.F.R. 121.103. The term "number of employees" is defined in 13 C.F.R. 121.106. A business concern may be in the form of an individual proprietorship, partnership, limited liability company, corporation, joint venture, association, trust, or cooperative. Further information may be obtained at http://sba.gov/size, or by contacting the Small Business Administration's (SBA) Government Contracting Area Office or Office of Size Standards.

Grant Description

This funding opportunity announcement (FOA) solicits Small Business Innovation Research (SBIR) grant applications that propose to develop novel pharmacologic agents for brain research related to mental disorders, including research aimed at discovering new drugs for these disorders. In addition, this FOA solicits SBIR grant applications that propose to take existing, promising compounds through the next step of drug discovery and development. Finally, this FOA also encourages SBIR grant applications designed to study the effectiveness of novel interventions.

Link to Full Grant Announcement

http://grants.nih.gov/grants/guide/pa-files/PA-06-027.html http://grants.nih.gov/grants/guide/pa-files/PA-06-027.html

Grant Announcement Contact

Webmaster, NIH, Webmaster, Phone not available, Fax not available, Email FBOWebmaster@mail.nih.gov FBOWebmaster@mail.nih.gov Webmaster, NIH

Similar Government Grants

• Pediatric Suicide Prevention in Emergency Departments (U01)

• Reducing the Duration of Untreated Psychosis in the United States (R34)

• Reducing the Duration of Untreated Psychosis in the United States (R01)

• Eradication of HIV-1 from CNS Reservoirs: Implications for Therapeutics (R21)

• Eradication of HIV-1 from CNS Reservoirs: Implications for Therapeutics (R01)

• Development of Biomarkers for Mental Health Research and Clinical Utilities: (STTR [R41/R4...

• Development of Biomarkers for Mental Health Research and Clinical Utilities (SBIR [R43/R44...

• Pharmacologic Agents and Drugs for Mental Disorders (STTR [R41/R42])

More Grants from the National Institutes of Health

• NIAMS Clinical Trial Outcome Instrument Development Grant Program (U01)

• Biophysical and Biomechanical Aspects of Embryonic Development (R01)

• Biophysical and Biomechanical Aspects of Embryonic Development (R21)

• Dual Purpose with Dual Benefit: Research in Biomedicine and Agriculture Using Agricultural...

• MARC Undergraduate Student Training in Academic Research (U-STAR) National Research Servic...